Radioimmunoassay of the anabolic agent zeranol. V. Residues of zeranol in the edible tissues, urine, faeces and bile of steers treated with Ralgro

Two trials were conducted on steers implanted with zeranol (Ralgro) to determine the edible tissue residues and the secretion pattern in faeces, urine and bile of zeranol residues throughout and beyond the recommended withdrawal period (70 days) for this drug. In the first trial there was considerable variation in the zeranol residue concentration in all edible tissues, the highest concentrations found in the liver being significantly above the control values (P less than 0.05). In the other tissues, only fat sampled 14 days after implanting was significantly above the control value (P less than 0.05). The zeranol concentration in bile samples obtained at slaughter [70 days (18), 90 days (5) and 120 days (2)] were all higher than the apparent concentration in the bile of untreated steers. The mean concentration of zeranol in the faeces and urine varied from day to day and between animals sampled on the same day following implantation. The highest mean concentrations were observed during the first 40 days following implanting, declining steadily to approach the control values 70 days after implantation. The second trial using steers prepared with bile duct re-entrant cannulae resulted in a similar pattern of zeranol excretion in bile, faeces and urine. The highest concentrations of zeranol were observed in bile and ranged from 24 to 34 micrograms/l; there was considerable variation between animals and within animals sampled on successive days. Although the concentration declined steadily, zeranol was still readily detectable 120 days after implanting.(ABSTRACT TRUNCATED AT 250 WORDS)     

Radioimmunoassay of the anabolic agent zeranol. III. Zeranol concentrations in the faeces of steers implanted with zeranol (Ralgro)

Using a monoclonal antibody raised against zeranol, a radioimmunoassay has been validated for the determination of zeranol residues in the faeces of treated steers. The limit of decision defined as the mean apparent concentration of zeranol in the faeces of untreated cattle + 3 SD was 1 ng/g faeces. In a trial in which 27 steers were implanted with zeranol (36 mg) at the base of the ear and six steers were sham implanted, the mean maximum concentration of zeranol in faeces was 5.8 ng/g on Day 15 following implanting, declining to 1.67 ng/g on Day 34 following implanting. During this period there was a marked variation between animals sampled on the same day following implanting. At no time during the trial did the apparent concentration of zeranol in the faeces of untreated animals rise above 0.91 ng/g, which is below the limit of decision for this assay.     

Radioimmunoassay of the anabolic agent zeranol. IV. The determination of zeranol concentrations in the edible tissues of cattle implanted with zeranol (Ralgro)

Rapid solvent extraction combined with a radioimmunoassay using a monoclonal antibody raised against a derivative of zeranol has been used to measure the residues of the anabolic agent zeranol in the edible tissues (muscle, liver, kidney and fat) of cattle treated with Ralgro. Calibration curves, both with and without, tissue extracts exhibit good parallelism. Regression analysis for the extraction of zeranol from tissues dosed with standard amounts of zeranol have correlation coefficients of 0.979, 0.991, 0.986 and 0.985 for muscle, liver, kidney and fat, respectively. The limits of decision defined as the mean value + 3 SD for the concentrations apparently observed (noise) in tissues from animals not treated with Ralgro were 278, 121, 373 and 110 ng/kg for muscle, fat, liver and kidney, respectively. In the tissues of 4 cows implanted with Ralgro (36 mg), and sampled 70 days after implanting, the highest concentration of zeranol in each tissue was 232 ng/kg (muscle), 391 ng/kg (liver), 287 ng/kg (kidney) and 293 ng/kg (fat), and residues were detected in all samples of fat (4), 3 kidney samples and 1 liver sample.     

A radioimmunoassay method for the measurement of residues of the anabolic agent, hexoestrol, in tissues of cattle and sheep

A radioimmunoassay (RIA) method for hexoestrol using an antiserum against hexoestrol-carboxypropyl ether-BSA and H³-hexoestrol was used to measure the concentrations of residues of hexoestrol in 0.1 ml biological fluids and 1 g edible tissues of implanted cattle and sheep. A preliminary ether extraction of biological fluids was necessary before RIA. The ether extract from tissues was further purified by solvent partition and silica gel column chromatography before RIA. Conjugates of hexoestrol were measured after enzymatic hydrolysis to free hexoestrol. In untreated animals residues were either not detected or very low in all tissues except urine from sheep. The method has a lower limit of detection of approximately 0–10 pg/ml for biological fluids in cattle and 20–100 pg/g for tissues in both sheep and cattle but the lower limit of detection in sheep urine was 70–294 pg/ml urine. In two heifers implanted with 60 mg hexoestrol and slaughtered 2 and 7 days after implantation, residues of hexoestrol were detected in all tissues except muscle with highest concentrations between 2 - 17 ng/g in urine, bile and kidney. The concentration of residues in steers which had been implanted with 45 mg or 60 mg hexoestrol and slaughtered at 90 days after implantation were 0, < 50, 46–96 and 200 pg/ml or g of plasma, muscle, liver and urine, respectively. The concentrations of hexoestrol in sheep implanted with 15 ml hexoestrol and slaughtered after 60 days were 70, 0, 964, 3100 and 4074 pg/g or ml of muscle, fat, liver, kidney and urine, respectively. No hexoestrol was found in control untreated cattle and sheep. It was concluded that some residues of hexoestrol were present in the excretory fluids and tissues of cattle and sheep which had been implanted with hexoestrol at the recommended dose and slaughtered after the recommended withdrawal periods. However, the concentrations of hexoestrol in muscle and fat were extremely low or not detectable. The method could be used for the routine screening of animals for treatment with hexoestrol.     

Effect of zeranol implantation on body weight changes in zebu crossbred cattle grazing tropical pasture

Nine experiments on the effect upon bodyweight change of subcutaneous ear implantation of 36 mg zeranol in 605 Bos indicus crossbred cattle were conducted. Bullocks aged 3 to 4 years, steers aged 18 months and entire heifers aged 18 to 30 months were used over the period January to August, 1980. They were grazed on 6 commercial farms in tropical northern Australia. Seven of the experiments examined the results of single implantation after the initial 60 to 97 days. Growth rates of untreated cattle in the January to May period ranged from 0.43 kg/day over 97 days in heifers to 1.07 kg/day in bullocks. Bodyweight gains attributed to zeranol ranged from 1.8 kg (4.3% increase) over 97 days in heifers (NS) to 22.3 kg (28.9% increase) over 90 days in 18 month-old steers (P < 0.01). The significant bodyweight responses to zeranol treatment in all 5 experiments involving older 3-to 4-year-old bullocks have not been previously reported. Hot dressed weights of the zeranol-treated bullocks were significantly heavier than the untreated controls and dressing percentages were similar. Increases in bodyweight attributable to implantation with zeranol yielded 50 to 54% saleable carcase weight. Single-, repeat-, and non-implanted treatments were compared over 186 days from January to August. Both zeranol treatments significantly out-performed the controls (P < 0.05), and the repeat-implanted bullocks gained 9.2 kg more than the single-implanted bullocks (P<0.10) in spite of bodyweight tosses recorded in the 3 treatments over the final 105 days. In 2 experiments bullocks implanted once in January/February were weighed in August to monitor compensatory bodyweight changes after April/May. The cattle retained 72.4% and 92.6% of the original bodyweight advantage attributed to zeranol treatment, depending upon whether they lost or gained in bodyweight respectively during the April/May to August period. The commercial relevance of these results is discussed and suggestions are made for further work.     

Effect of zeranol on sexual development of crossbred bulls

Three groups of 1/2 Simmental X 1/4 Brahman X 1/4 Hereford bull calves were used during two different years to study effects of zeranol on sexual development. At 154 d of age, half the calves were implanted with 36 mg zeranol and half, not implanted, served as controls. Implanted calves were reimplanted at 90-d intervals throughout the trial (9 mo) each year. Trial 1 was conducted with 24 calves and Trial 2 was conducted the following year with 10 bulls. Twenty-four days after weaning (200 d of age) and at 28-d intervals thereafter, bulls in drylot in Trial 1 were weighted, scrotal circumference (SC) was measured and an ejaculate of semen was collected by electroejaculation to determine puberty. At these times, bulls were given 200 micrograms of GnRH i.m. and blood was collected at 0, 1, 2, 3, 4 and 5 h after GnRH. Serum concentrations of LH and testosterone (TEST) were determined. At slaughter, testis weight, length and circumference and pubertal status were recorded. Bulls implanted with zeranol had smaller SC than control bulls during the entire 9-mo period (P less than .0001). More control bulls reached puberty than did implanted bulls (82.4 vs 23.5%, respectively; P less than .001). Control bulls had larger testis measurements at slaughter (P less than .0001). Implants did not alter total weight gain or ADG (P greater than .10).(ABSTRACT TRUNCATED AT 250 WORDS)     

Detection of zeranol in the blood of ram lambs by a radioimmunoassay technique

Plasma separated from jugular blood samples from six weaned ram lambs was examined for zeranol after the lambs had been implanted, behind the left ear, with a 12 mg pellet. The results showed that the ipsilateral vein contained significantly more zeranol for up to 100 days after implantation; by 145 to 175 days the difference between the ipsi- and contralateral veins was no longer significant. Massage of the implant site did not increase the rate of release of zeranol from the residual mass.     

Effects of zeranol implants on post-castration response in calves

SUMMARY Suckling and yearling calves were surgically castrated and one half of each group implanted with 36 mg zeranol at time of castration. Both treated and control cattle of each class were maintained as a group and evaluated for swelling of the scrotum, inflammation and healing, plasma prostaglandin levels and weight gain. Swelling and inflammation of the scrotum were less in treated suckling calves than in controls at both 7 and 14 d after castration, though this difference was not statistically significant. In yearlings at 7 d after castration, treated cattle had more swelling than controls; however at 14 d, treated cattle had less swelling and inflammation with only one treated yearling having an open scrotal wound versus 6 (P <.03) in the control group. Plasma prostaglandin levels as indicated by plasma malondialdehyde increased from d 0 to 14; however no significant treatment differences were observed for either age group. Suckling calves treated with zeranol gained 9.79 kg more (P <.03) than non-treated calves during the 97 d of trial while the yearlings treated with zeranol gained 16.78 kg more (P <.01) than controls during 102 d. It is concluded from the increased growth and reduced scrotal swelling and inflammation in treated cattle that zeranol implantation could possibly have a beneficial effect in improving the healing process after castration.     

Comparison of the effects of injections of nortestosterone phenylpropionate at single and multiple sites in cattle on the detection of its residues in plasma, urine and bile

The synthetic androgen 17 beta-19-nortestosterone (beta-NT) has been used illegally as a growth promoter in cattle production in the European Union. The elimination of beta-NT and its metabolites in plasma and urine was studied in cattle which had received intramuscular injections of its phenylpropionate ester (NTPP) at either single or multiple sites at a dose rate of 1 mg/kg bodyweight. In both groups, the plasma concentrations of beta-NT, measured by enzyme immunoassay, were consistently greater than the assay's limit of quantification (0.24 ng/ml) during days 1 to 7 of the study. The mean (sd) maximum plasma concentration (Cmax) was significantly greater in the multiply injected animals (4.4 [0.48] v 2.7 [0.15] ng/ml), but other plasma pharmacokinetic parameters, AUC, CL, T1/2 beta, Tmax and MRT, were not significantly different in the two groups. The equivalent urinary concentrations exceeded the limit of quantification of the assay (4.5 ng/ml) for up to 24 days after injection. In a second study, the biliary concentrations of beta-NT and its 17 alpha-epimer (alpha-NT) were measured by gas chromatography-high resolution mass spectrometry after cattle were injected intramuscularly at either single or multiple sites with NTPP. Only alpha-NT was detected in bile for up to 62 days after injection at concentrations above the limit of quantification of the assay (0.7 ng/ml). It is concluded that in some animals, intramuscular injections of NTPP at several sites may decrease the period after injection during which free beta-NT and its metabolites are detectable in plasma and urine. After the injection of NTPP, alpha-NT was detected in bile for longer than it was detected in plasma or urine.     

Pharmacokinetics of tulathromycin in nonpregnant adult ewes

The objectives of this study were to determine plasma concentrations and pharmacokinetic parameters of tulathromycin after a single subcutaneous administration in the cervical region in sheep using the cattle labeled dose of 2.5 mg/kg. Six adult healthy ewes were administered tulathromycin on day 0. Blood samples were collected just prior to dosing and at selected time points for 360 h. Plasma samples were analyzed to determine tulathromycin concentrations, and noncompartmental analysis was performed for pharmacokinetic parameters. The mean maximum plasma concentration was 3598 ng/mL, the mean time to maximum concentration was 1.6 h, and the apparent elimination half‐life ranged from 68.1 to 233.1 h (mean 118 h). When comparing our results to goats and cattle, it appears sheep are more similar to cattle in regard to the concentrations observed and pharmacokinetic parameters. In summary, the pharmacokinetics of tulathromycin in sheep appear to be similar enough to those in goats and cattle to recommend similar dosing (2.5 mg/kg SC), assuming that the target pathogens have similar inhibitory concentrations.     

Sexual development in beef bulls following zeranol implants

Two trials were conducted to study the effect of zeranol implants on growth and sexual development of bull calves. Trial 1 compared the effects of implanting with 72 mg of zeranol at 48 d of age (branding), at 215 d of age, or at both times with nonimplanted control bulls. Implanting at branding resulted in decreased scrotal circumference, testicle weight and proportion of bulls that could produce an ejaculate at 14 mo of age (P less than .01). Implanting at 215 d of age had no effect on any of these traits. Growth rate was not increased by implanting at either time but was decreased (P less than .02) in animals implanted at both times when compared with control bulls. In trial 2, both bulls and steers were implanted with zeranol and compared with nonimplanted control bulls and steers. Thirty-six-milligram implants were given at 21, 103, 260 and 343 d of age. Scrotal circumference, testicle weight and serum testosterone concentrations decreased (P less than .01) and the occurrence of penis abnormalities increased (P less than .01) in implanted bulls compared with control bulls. By the time of slaughter, however, testosterone concentrations were equal in control and implanted bulls; and the difference in scrotal circumference was diminishing. This is interpreted as evidence that as the bulls get older, they can overcome the effect of the implants. Carcass weights were heavier in implanted steers than in control steers but were lighter in implanted bulls than in control bulls (P less than .02). Carcasses of implanted bulls had higher quality scores and more marbling than control bulls, but carcasses of implanted steers had lower quality scores and less marbling than control steers (both interactions, P less than .01). Implanting bulls with zeranol at an early age resulted in restricted sexual development but not in total sterility. Repeated zeranol implants throughout the growing and finishing phase enhanced carcass quality in bulls slaughtered at 14 to 16 mo of age.     

EFFECT OF SUBCUTANEOUS IMPLANTS OF ZERANOL ON WEIGHT GAINS OF CASTRATED CATTLE AT PASTURE†

SUMMARY Eight experiments involving a total of 480 castrated cattle grazing Australian pastures were conducted to assess the effect of subcutaneous implants of 36 mg zeranol on weight gain. A wide range of cattle ages, bodyweights and environmental and nutritional conditions was involved. Growth rates of untreated cattle ranged from minus 0.15 kg/day over 90 days to 1.23 kg/day over 52 days. In 5 experiments treated cattle were implanted at the commencement of the experiment only. The other 3 experiments compared responses to early, late and early plus late implantation. Weight gains from a single implantation ranged from 4.6 kg over 70 days to 16.8 kg over 60 days—an average increase in growth rate of 13.5%. Repeating implantation at a later date increased growth rate further and provided greater gains than a single implantation whether applied early or late. Carcase weights were measured in 2 experiments. In one, weight was increased by 7.2 kg (P < 0.01). In the other, cattle in both implanted and control groups lost weight over the duration of the experiment. Whilst the bodyweight of implanted cattle was less than that of untreated cattle the carcase weight of implanted cattle was 2.4 kg greater than for control cattle. Neither of these differences was significant (P > 0.10). No side effects were noted in any of the treated cattle.     

Plasma testosterone and LH responses to LHRH in double-muscled bulls treated with trenbolone acetate and zeranol

Twenty-four double-muscled Belgian White Blue bulls were assigned, according to body weight, to two groups with and without treatment with anabolic agents. Implants containing 140 mg trenbolone and 36 mg zeranol (Forplix) were inserted sc on the upper face of the ear flap. Plasma concentrations of testosterone and luteinizing hormone (LH) were determined at d 0, 30 and 60 of the experimental period. Mean testosterone levels at d 0 for treated and controls were, respectively, 2.1 and 1.7 ng/ml during the 10-h sampling period. At d 30 and 60, testosterone levels were strongly depressed in implanted bulls (.2 ng/ml) as compared with 2.5 and 1.7 ng/ml in control bulls (P less than .001 at d 30 and P less than .01 at d 60). Average plasma LH concentrations were identical in the two groups at d 0 and 60 (1.1 and 1.5 ng/ml, respectively), but showed a slight decrease at d 30 in the treated group (P less than .10). The pulsatile character of LH and testosterone profiles was abolished by the Forplix treatment. Luteinizing hormone-releasing hormone (LHRH) injection at d 0 was followed in both groups by an immediate and sharp increase in plasma LH concentrations. The LH response reached a maximal value between 20 to 40 min postinjection and then declined rapidly. On the contrary, Forplix treatment strongly reduced LH and testosterone responses to LHRH stimulation in treated animals. Average daily gain and feed to gain ratios were 1.087 +/- .127 and 7.52 +/- .32 kg, respectively, for the control bulls and 1.335 +/- .092 and 6.24 +/- .24 kg for the Forplix-treated bulls, thus clearly showing a beneficial effect of Forplix treatment.     

Growth, carcass and palatability traits of intact males and steers implanted with zeranol or estradiol early and throughout life

This study was conducted to assess the impact of implanting intact beef males with protein anabolic agents at varying intervals throughout life. Ninety-six intact males were assigned to three implant treatments: 1) not implanted, 2) implanted at 9 wk of age, weaning and at 56-d intervals thereafter with a 36-mg zeranol implant or 3) estradiol implant at 9 wk of age and 68 d post-weaning. During the 118-d, post-weaning growing period, eight animals per treatment (one replication) were castrated. After a 114-d finishing period, cattle were slaughtered (average age of 13 to 14 mo). Feedlot performance, carcass and palatability data were obtained. Average daily gains and feed efficiency did not differ (P greater than .05) between zeranol and estradiol-implanted intact males. Regardless of implant treatment, steers had lighter carcass weights (P less than .05) and higher (P less than .01) quality grades than intact males. Implanting either intact males or steers with zeranol or estradiol resulted in higher (P less than .05) numerical yield grades. Quality grades were higher in zeranol-implanted cattle than the non-implanted or estradiol-implanted cattle. Intact males implanted with zeranol were similar in carcass fatness to zeranol-implanted steers. No differences (P greater than .05) in tenderness or connective tissue were detected. Implanting intact males early and throughout life with zeranol made them similar to steers in fatness, while estradiol implantation had few effects on carcass and palatability traits of intact males or steers.     

Comparative study of the cardiovascular effects of losartan in normal and in water- and salt-depleted sheep

The cardiovascular effects of losartan, a non-peptidic angiotensin II (ANG II) receptor antagonist, were studied in sheep. Eight normotensive, conscious sheep were tested twice: first under normal conditions and second when subjected to water and electrolytic depletion (furosemide 5 mg/kg twice a day for 3 days). Intravenous injection of 30 mg/kg losartan lowered the mean arterial blood pressure (MABP) in both control and water- and electrolyte-depleted sheep alike. The maximal decrease in MABP was significantly greater in diuretic-treated sheep than in controls (20.0 +/- 2.7 vs 9.3 +/- 1.1 mmHg) and occurred earlier (8.0 +/- 3.3 min vs 12.1 +/- 2.9 min). The decrease in blood pressure was associated with tachycardia in both controls and diuretic-treated sheep (+5.5 +/- 1.8 vs +11.3 +/- 3.9 beats/min). The vasopressor response to 0.1 microg/kg ANG II administered 30 min after losartan was completely antagonized. Two hours after losartan administration, MABP was on the increase in all animals and ANG II receptor blockade was partially obliterated in control sheep. The more marked cardiovascular effects recorded in diuretic-treated sheep as compared to control animals were associated with an increased activation of the renin-angiotensin system (plasma renin concentration: 6.51 +/- 1.33 vs 1.42 +/- 0.37 ng angiotensin I/ml/hr).     

Evaluation of growth, carcass traits and reproductive organs of young boars in response to zeranol implantation

Two experiments were conducted to evaluate the effect of implants containing zeranol on growth rate, carcass composition, palatability and reproductive organ development of intact male pigs. In Exp. 1, three treatment groups were evaluated: control barrows, intact control boars and implanted boars (implanted at either 28, 56 or 112 d of age with one 12-mg dose of zeranol). In Exp. 2, four treatment groups were evaluated: control barrows, intact control boars, boars implanted at 28 d with 24 mg of zeranol (single implant) and boars implanted at 28 d and re-implanted at 56 and 112 d of age with 24 mg of zeranol (triple implant). Differences for average daily gain and carcass traits were not consistent between treatment groups with the exception of 10th rib fat, where barrows were fatter than boars. There were no differences among treatments due to zeranol for the reproductive organ characteristics, with the exception that bulbourethal gland and teat weights were heavier for boars in Exp. 2. Penis weights and lengths were lower for barrows in both experiments. Juiciness, tenderness, Warner-Bratzler shear force, pork flavor intensity and sensory scores were not consistently affected by male condition or zeranol treatment. In two of the three comparisons, implanted boars had higher off-flavor intensity scores in Exp. 1, but no treatment difference was observed in Exp. 2. Zeranol implantation did not result in significant changes in growth rate, development of reproductive organs or carcass characteristics of young boars.     

Pharmacokinetics of eprinomectin in plasma and milk following topical administration to lactating dairy cattle

The pharmacokinetics and mammary excretion of eprinomectin were determined in cattle following topical administration at a dose rate of 0.5 mg kg(-1). The kinetics of plasma and milk concentrations were analysed using a one-compartment model. The maximum plasma concentration of 43.76 ng ml(-1)occurred 2.02 days post administration, and the mean residence time was 4.16 days. Eprinomection was detected in the milk at the first sampling time and thereafter for at least 15 days. Comparison of the milk and plasma data demonstrated the parallel disposition of the drug in the milk and plasma with a milk / plasma concentration ratio of 0. 102+/-0.048. The amount of drug recovered in the milk during this period was 0.109% +/- 0.038 of the total administered dose. This very low extent of mammary excretion resulted in low concentrations of eprinomectin in milk. This supports the permitted use in lactating cattle, as the maximum level of residue in milk did not exceed the maximum acceptable limit of 30 ng ml(-1).     

Ruminal escape protein supplementation and zeranol implantation effects on performance of steers grazing winter annuals.

Fifty-four crossbred steers (275 kg) were assigned randomly to one of three isoenergetic but not isonitrogenous ruminal escape protein (EP) supplements: high ruminal escape protein (HEP), low ruminal escape protein (LEP), or corn. The supplements contained corn, distillers' dried grains with solubles (DDGS), and fish meal. Supplements were fed at approximately 1.5 kg/d; the HEP and LEP supplements provided .25 and .12 kg more EP per day than corn, respectively. These supplements also supplied .20 and .10 kg more CP per day than corn. Fish meal and DDGS provided 66.7 and 33.3% of the supplemental EP, respectively. One-half of the steers in each supplement treatment were implanted once with 36 mg of zeranol. Steers grazed wheat (Triticum aestivum L.)-annual ryegrass (Lolium multiflorum Lam.) pastures for 73 d (March 1 to May 12). Daily gains (kg/d) increased linearly (P less than .07) as EP increased (HEP, 1.61; LEP, 1.54; corn, 1.47); responses were apparent only during the later periods as forage quality declined. Zeranol implants increased (P less than .02) ADG (kg/d) by 9.7% (1.58 vs 1.44). After grazing, all cattle were fed a finishing ration for 76 d. Pre-feedlot EP level produced a negative linear (P less than .04) response on feedlot ADG (kg/d) (HEP, 1.44; LEP, 1.50; corn, 1.59). Zeranol implantation during the grazing phase did not affect (P greater than .2) performance during the feedlot phase or carcass characteristics other than increased ribeye area (P less than .08). Compensatory feedlot performance negated all weight gain advantages elicited by EP supplementation during the grazing period.(ABSTRACT TRUNCATED AT 250 WORDS)     

Pharmacokinetics of Selamectin in Dogs after Topical Application

Some pharmacokinetic parameters of selamectin were determined in male (n = 5) and female (n = 5) Beagle dogs following a topical application at a dose rate of 6 mg/kg. The plasma concentration versus time data for the drug were analysed using a one-compartment model. The maximum plasma concentrations of 12.72 +/- 5.13 ng/ml for males and 22.65 +/- 11.95 ng/ml for females occurred around 5 days after administration. The area under the concentration-time curve (AUC) was 192.08 +/- 63.85 ng.day/ml for males and 370.97 +/- 146.87 ng.day/ml for females. The mean residence time was the same in males and females (12.55 days). This study reveals a sex-influence on the disposition of selamectin in the plasma of dogs, which implies that further information will be needed for correlation with efficacy studies in dogs.